Renalytix PLC is a biotechnology company that specializes in developing and commercializing diagnostic solutions for kidney disease. The company was founded in 2018 as a collaboration between the Icahn School of Medicine at Mount Sinai in New York City and the University of Glasgow in Scotland. Renalytix's mission is to improve the detection, diagnosis, and management of kidney disease, which is a prevalent and serious global health issue.
Renalytix focuses on leveraging advanced artificial intelligence and machine learning technologies to develop innovative diagnostic tools and algorithms. These solutions aim to enable early and accurate detection of kidney disease, allowing healthcare providers to intervene and manage the condition more effectively, potentially improving patient outcomes.
The company's flagship product is KidneyIntelX™, a novel urine-based diagnostic test that combines molecular biomarkers with patient clinical data to assess a patient's risk of progressive kidney function decline. KidneyIntelX™ has received FDA breakthrough designation and is designed to aid in the risk assessment and management of patients with Type 2 diabetes and chronic kidney disease (CKD).
In addition to its diagnostic solutions, Renalytix has been actively pursuing partnerships and collaborations with leading healthcare organizations and research institutions to expand the applications of its technology and drive further innovation in the field of kidney disease diagnosis and management.
The company's commitment to advancing kidney disease diagnostics and its focus on precision medicine align with the growing need for more effective and personalized approaches to address the global burden of kidney disease. By enabling earlier detection and intervention, Renalytix aims to make a significant impact on patients' lives and the overall healthcare system.